Corvus Pharmaceuticals, Inc.

The company is a clinical-stage biopharmaceutical enterprise focused on discovering and developing targeted therapies for immune-mediated diseases, inflammatory conditions, and cancers. Its research targets proteins critical to immune cell differentiation and function. The pipeline features soquelitinib, an oral covalent ITK inhibitor being evaluated in clinical studies for peripheral T-cell lymphomas and atopic dermatitis. Additional clinical-stage assets include ciforadenant, an adenosine A2A receptor antagonist under investigation for metastatic renal cell carcinoma, and mupadolimab, a B-cell-activating monoclonal antibody directed against CD73. Because the company does not operate commercial products, its programs address patient populations in specialized clinical trials.

The company operates without internal manufacturing facilities, relying entirely on third-party contract manufacturers to produce, fill, label, package, and distribute its investigational therapies. Its operations and intellectual property span international jurisdictions, maintaining patent protections and applications across the United States, Europe, Canada, Japan, South Korea, Australia, and China. The provided text does not disclose the location of the company's corporate headquarters.

Summary of the business section of Corvus Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 37 total employees, all of whom were full-time and 29 of whom were primarily engaged in research and development activities.”